1. Population Pharmacokinetics of Tracers: A New Tool for Medical Imaging?

   • Peggy Gandia
   • Cyril Jaudet
   • Didier Concordet

   Leading Article 09 July 2016 Pages: 101 - 106

   

2. Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus

   • Tian Yu
   • Elena Y. Enioutina
   • Catherine M. Sherwin

   Review Article 06 July 2016 Pages: 107 - 125

   

3. Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies

   • Amélie Marsot
   • Romain Guilhaumou
   • Olivier Blin

   Review Article 21 June 2016 Pages: 127 - 138

   

4. Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide

   • Nianhang Chen
   • Simon Zhou
   • Maria Palmisano

   Review Article Open access 28 June 2016 Pages: 139 - 152

   

5. Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment

   • Amit Khatri
   • Sandeep Dutta
   • Rajeev M. Menon

   Original Research Article 07 July 2016 Pages: 153 - 163

   

6. Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study

   • Francis Lévi
   • Abdoulaye Karaboué
   • Etienne Chatelut

   Original Research Article 08 July 2016 Pages: 165 - 177

   

7. Pharmacokinetics, Biotransformation, and Excretion of [¹⁴C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis

   • Raju Subramanian
   • Xiaochun Zhu
   • Gary L. Skiles

   Original Research Article Open access 12 August 2016 Pages: 179 - 192

   

8. Discrepancies between the Cockcroft–Gault and Chronic Kidney Disease Epidemiology (CKD-EPI) Equations: Implications for Refining Drug Dosage Adjustment Strategies

   • Pierre Delanaye
   • Fabrice Guerber
   • Hans Pottel

   Original Research Article 14 July 2016 Pages: 193 - 205

   

9. Comment on: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”

   • Kirollos S. Kamel
   • Paul K. L. Chin
   • Murray L. Barclay

   Letter to the Editor 20 December 2016 Pages: 207 - 208

10. Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”

    • Stephan Glund
    • Paul Reilly
    • Joachim Stangier

    Letter to the Editor Open access 27 December 2016 Pages: 209 - 210

11. Comment on: “Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer”

    • Nuggehally R. Srinivas

    Letter to the Editor 05 November 2016 Pages: 211 - 212

12. Author’s Reply to Srinivas: “Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer”

    • Steven Xu
    • Peter De Porre

    Letter to the Editor 05 November 2016 Pages: 213 - 214